Loading
Latest filing published 19 Jan 2024 for Clearside Biomedical, Inc., €21k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
George M. Lasezkay (chief executive) discloses dealings in Clearside Biomedical, Inc. to SEC (Form 4). The record holds 18 filings, for trades running from 7 August 2019 to 19 January 2024.
On the open market, the record shows 1 purchase worth €13k and 11 sales worth €220k. Sales outweigh purchases by €207k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 6 share grants. So far in 2024, the count stands at no purchases and 1 sale.
The record was last updated on 19 January 2024 with an open-market sale (€21k) in Clearside Biomedical, Inc. The latest purchase dates back some time: it was published 2,538 days ago, on 12 November 2019. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations